GHB: a promising biomarker to extend detection, still awaiting validation

GHB is difficult to detect, notably because it is rapidly eliminated. A controlled trial involving 30 participants identifies a marker, GHB-β-ribose, whose urinary concentrations remain elevated for up to 24 hours after intake. This is a promising lead for forensic toxicology, not yet evidence of a reliable test under real-world conditions.

Illustration of blood and urine samples intended for research into a biomarker of GHB intake.
Gadgets & TechEditorial illustration, not study data.

Why detecting GHB is challenging

GHB is suspected of being involved in drug-facilitated sexual assaults. Detecting it presents several challenges: its rapid elimination, its natural presence in the body and its possible formation after sample collection. Detecting GHB is therefore not always enough to distinguish external intake from these other sources.

The researchers’ aim was to find a biomarker that could extend the detection window. In other words, a measurable trace that remains informative when detecting GHB itself becomes difficult.

A marker identified in a controlled trial

The researchers used samples from 30 participants in a randomized, controlled, double-blind trial. Participants had received either a placebo or a single oral dose of sodium oxybate, a salt of GHB. Blood and urine samples were collected over five days.

An untargeted metabolomics analysis was used to search for candidate markers. The most promising was identified as GHB-β-ribose through chemical synthesis and liquid chromatography coupled with tandem mass spectrometry.

After intake, concentrations of this marker were elevated in both blood and urine. The abstract reports elevated urinary concentrations for up to 24 hours and mentions comparisons with endogenous levels in the placebo group as well as with real forensic cases.

An analytical lead, not proof of assault

These findings suggest that GHB-β-ribose could help detect GHB intake over a longer period. However, they do not establish the proportion of instances of intake correctly detected or the risk of false-positive results: these performance measures are not detailed in the supplied abstract.

The trial involved a single, controlled administration. Its applicability to more variable forensic situations remains to be established. Even a reliable marker of intake would not, on its own, demonstrate administration without someone’s knowledge or an assault.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. The sample size is limited to 30 participants. The abstract does not detail diagnostic performance, funding or conflicts of interest. The duration reported for blood appears without a unit in the supplied excerpt and is therefore not repeated here.

What we can take away

GHB-β-ribose is a promising candidate for extending the detection window for GHB intake. The available data are insufficient to describe it as a validated forensic test.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.